--- title: "NovelStem International (NSTM) stock and investor profile" url: "https://aibio.space/companies/novelstem-international/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NovelStem International Corp. (OTC: NSTM), United States. The directory classifies it as Biotechnology." --- NSTM NovelStem International Corp. OTC · United States # NovelStem International (NSTM) news Distress · 2025-05-15 ## [NovelStem International delays first-quarter 2025 report as auditors finish review](https://aibio.space/news/novelstem-international-delays-first-quarter-2025-report-auditors/) NovelStem says its auditors need more time to finish their review of the March quarter, and it expects to file within five calendar days after the due date. NewStem, in which it holds about 31%, ceased operations and began liquidation in October 2024. ## Latest NovelStem International news We have not published a story on NovelStem International yet. When there is news, it will appear here. ## NovelStem International at a glance - **Ticker**: NSTM - **Listing**: OTC - **Country**: United States - **Cash, Jun 30, 2025**: $1,106 ### Related companies - [Statera Biopharma](https://aibio.space/companies/statera-biopharma/) OTC: STAB - [Exicure](https://aibio.space/companies/exicure/) NASDAQ: XCUR - [InVitro International](https://aibio.space/companies/invitro-international/) OTC: IVRO - [SORRENTO THERAPEUTICS INC](https://aibio.space/companies/sorrento-therapeutics/) OTC: SRNE - [AnaptysBio](https://aibio.space/companies/anaptysbio/) NASDAQ: ANAB - [BridgeBio Pharma](https://aibio.space/companies/bridgebio-pharma/) NASDAQ: BBIO - [MiNK Therapeutics](https://aibio.space/companies/mink-therapeutics/) NASDAQ: INKT - [Shattuck Labs](https://aibio.space/companies/shattuck-labs/) NASDAQ: STTK ### Also on OTC - [Integrated BioPharma](https://aibio.space/companies/integrated-biopharma/) INBP - [GlobeStar Therapeutics](https://aibio.space/companies/globestar-therapeutics/) GSTC - [Innovation Pharmaceuticals](https://aibio.space/companies/innovation-pharmaceuticals/) IPIX - [CYANOTECH CORP](https://aibio.space/companies/cyanotech/) CYAN - [Altamira Therapeutics](https://aibio.space/companies/altamira-therapeutics/) CYTOF - [CASI Pharmaceuticals](https://aibio.space/companies/casi-pharmaceuticals/) CASIF ## What NovelStem International does NovelStem International Corp. is a holding company whose principal remaining asset is the right to profits from a license held by Yissum Research Development Company, the technology transfer company of the Hebrew University. Its former affiliate NewStem Ltd., an Israeli biotech, was developing a haploid human pluripotent stem cell platform for oncology drug discovery and a personalized diagnostic to detect mutations that may confer resistance to anti-cancer drugs. NewStem holds a CE Mark for its in vitro diagnostic device but has no FDA approved device. NewStem ceased operations in October 2024 and completed its liquidation in October 2025, and the technology reverted to the original licensor. NovelStem retained a financial interest of up to $3,750,000 in any future licensing. In May 2025 NovelStem sold its 50% interest in NetCo Partners, a joint venture that owns the Net Force publishing franchise, to settle a litigation funding liability. The company says it depended entirely on earnings and cash from its investments in NewStem and NetCo. | Product or program | What it is | Stage | |---|---|---| | NewStem Software Diagnostic Device (NSDD) | Software in vitro diagnostic device under EU regulation | CE marked since March 2022; no FDA approved device | | Haploid stem cell oncology discovery platform | Genome-wide screening platform for oncology drugs | NewStem ceased operations October 2024 | Summarised from the company's [10-K filed Mar 26, 2026](https://www.sec.gov/Archives/edgar/data/912544/000149315226012736/form10-k.htm). ## NovelStem International annual financials | Line | FY2025 | FY2024 | |---|---|---| | Net income (loss) | [$2.4 million](https://www.sec.gov/Archives/edgar/data/912544/000149315226012736/) | [-$3.2 million](https://www.sec.gov/Archives/edgar/data/912544/000149315226012736/) | | Cash from operations | [-$167,633](https://www.sec.gov/Archives/edgar/data/912544/000149315226012736/) | [-$271,964](https://www.sec.gov/Archives/edgar/data/912544/000149315226012736/) | | Cash and equivalents | | [$6,099](https://www.sec.gov/Archives/edgar/data/912544/000149315225011661/) | Latest balance sheet, Jun 30, 2025 (10-Q): cash and equivalents $1,106. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about NovelStem International What is the ticker symbol of NovelStem International? NovelStem International Corp. trades under the ticker NSTM on OTC. Where is NovelStem International listed? NovelStem International Corp. is listed on OTC. What is the SEC CIK of NovelStem International? The SEC Central Index Key (CIK) for NovelStem International Corp. is 912544. Its filings are on SEC EDGAR. How many shares does NovelStem International have outstanding? 49,332,455 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is NovelStem International listed under? Our directory records NovelStem International Corp. under United States. What does NovelStem International do? Our directory classifies NovelStem International Corp. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of NovelStem International? The ISIN recorded for NovelStem International Corp. is US67001V1098. Does aibio.space cover NovelStem International? aibio.space lists NovelStem International Corp. among 2,820 public biotech companies and publishes its news here as stories appear. Where is NovelStem International incorporated? SEC records list its state or country of incorporation as FL. What does NovelStem International develop? NovelStem International Corp. is a holding company whose principal remaining asset is the right to profits from a license held by Yissum Research Development Company, the technology transfer company of the Hebrew University. Its former affiliate NewStem Ltd., an Israeli biotech, was developing a haploid human pluripotent stem cell platform for oncology drug discovery and a personalized diagnostic to detect mutations that may confer resistance to anti-cancer drugs. What is NewStem Software Diagnostic Device (NSDD) from NovelStem International? NewStem Software Diagnostic Device (NSDD): Software in vitro diagnostic device under EU regulation Stage: CE marked since March 2022; no FDA approved device. What is Haploid stem cell oncology discovery platform from NovelStem International? Haploid stem cell oncology discovery platform: Genome-wide screening platform for oncology drugs Stage: NewStem ceased operations October 2024. Is NovelStem International profitable? NovelStem International Corp. reported net income of $2.4 million for the fiscal year ended Dec 31, 2025, and used $167,633 of cash in operations, per its annual report to the SEC. How much cash does NovelStem International have? $1,106 in cash at Jun 30, 2025, per its 10-Q. What is the latest NovelStem International (NSTM) stock news? Our latest story on NovelStem International, dated May 15, 2025: "NovelStem International delays first-quarter 2025 report as auditors finish review". NovelStem says its auditors need more time to finish their review of the March quarter, and it expects to file within five calendar days after the due date. NewStem, in which it holds about 31%, ceased operations and began liquidation in October 2024. [Source](https://aibio.space/news/novelstem-international-delays-first-quarter-2025-report-auditors/). ## Investor discussion: NovelStem International Members talk about NovelStem International (NSTM). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at NovelStem International, newest first. Each line links the filing it comes from. 1. 2026-03-26 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/912544/000149315226012736/form10-k.htm) 2. 2025-05-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/912544/000164117225010794/formnt10-q.htm) 3. 2025-04-07 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/912544/000164117225003031/form10-k.htm) 4. 2025-04-01 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/912544/000164117225001918/formnt10-k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:NSTM on TradingView](https://www.tradingview.com/symbols/OTC-NSTM/). ## SEC filings and registration - **SEC name**: NovelStem International Corp. - **CIK**: 912544 - **Industry (SIC)**: Retail-Retail Stores, NEC (5990) - **US tickers**: NSTM (OTC) - **State or country of incorporation**: FL - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 2255 GLADES RD, BOCA RATON, FL, 33431 - **Phone**: 5619988000 - **Shares outstanding**: 49,332,455 as of 2026-08-14 (10-Q filed 2026-08-14) - **Former names**: NovelStem International Corp; HOLLYWOOD MEDIA CORP; HOLLYWOOD COM INC ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/912544/000149315226038089/form10-q.htm) filed 2026-08-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/912544/000149315226023227/form10-q.htm) filed 2026-05-15 - [10-K](https://www.sec.gov/Archives/edgar/data/912544/000149315226012736/form10-k.htm) filed 2026-03-26 - [10-Q](https://www.sec.gov/Archives/edgar/data/912544/000149315225021861/form10-q.htm) filed 2025-11-12 - [10-Q](https://www.sec.gov/Archives/edgar/data/912544/000149315225011661/form10-q.htm) filed 2025-08-06 - [10-Q](https://www.sec.gov/Archives/edgar/data/912544/000164117225011514/form10-q.htm) filed 2025-05-19 - [10-K](https://www.sec.gov/Archives/edgar/data/912544/000164117225003031/form10-k.htm) filed 2025-04-07 - [10-Q](https://www.sec.gov/Archives/edgar/data/912544/000149315224045856/form10-q.htm) filed 2024-11-14 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000912544), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details NovelStem International Corp. is a public biotech or pharmaceutical company listed on OTC under the ticker NSTM, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: NovelStem International Corp. - **Ticker**: NSTM - **Listing**: OTC - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US67001V1098 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-NSTM/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/novelstem-international/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "NovelStem International (NSTM) stock and investor profile", 2026-10-31, https://aibio.space/companies/novelstem-international/